Program
BCG Vaccine
Also written as “BCG”, “BCG for Therapeutic Use” and “Bacillus Calmette-Guerin”.
Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urinary Bladder Neoplasms · Tuberculosis · Alzheimer Disease · Melanoma, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Zhifei Biological Products | 41 open or running | phase 3since Mar 14, 2016 | Mar 5, 2015 | Apr 30, 2028phase 3 · NCT06747455 |
| ImmunityBio | 32 open or running | phase 3since Apr 20, 2026 | May 13, 2014 | Nov 2026phase 2 · NCT06829823 |
| Chengdu CoenBiotech | 21 open or running | phase 3since Jan 28, 2024 | Jan 28, 2024 | none ahead |
| AstraZeneca | 11 open or running | phase 3since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| Heat Biologics | 10 open or running | phase 2since Dec 5, 2013 | Dec 5, 2013 | none ahead |
| Laboratorio Pablo Cassará S.R.L. | 10 open or running | phase 3since Nov 14, 2012 | Nov 14, 2012 | none ahead |
| Merck | 11 open or running | phase 2since Feb 4, 2025 | Feb 4, 2025 | Sep 3, 2031phase 2 · NCT06833073 |
| Mindful Diagnostics and Therapeutics | 10 open or running | phase 2since Jun 24, 2020 | Jun 24, 2020 | none ahead |
| Pfizer | 11 open or running | phase 3since Nov 13, 2019 | Nov 13, 2019 | none ahead |
| Verity Pharmaceuticals | 11 open or running | phase 3since Jul 28, 2021 | Jul 28, 2021 | Feb 2029phase 3 · NCT05037279 |
Also a collaborator on its studies: Moderna, parexel and proswell-medical-corporation.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 14, 2012.
- May 13, 2014ImmunityBio's first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to ImmunityBioImmunityBio · NCT02138734 · 369 enrolled · United States, India, South Africa
- Mar 5, 2015Chongqing Zhifei Biological Products's first study: phase 2 study in TuberculosisNew to Chongqing Zhifei Biological ProductsChongqing Zhifei Biological Products · NCT02389322 · 1,044 enrolled · China
- Mar 14, 2016Phase 3 study in TuberculosisChongqing Zhifei Biological Products · NCT02795260 · 1,802 enrolled
- Nov 13, 2019Pfizer's first study: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNew to PfizerPfizer · NCT04165317 · 1,068 enrolled · United States, Australia, Belgium and more
- Jun 24, 2020Mindful Diagnostics and Therapeutics's first study: phase 2 study in Alzheimer DiseaseNew to Mindful Diagnostics and TherapeuticsMindful Diagnostics and Therapeutics · NCT04449926 · 49 enrolled · United States
- Jul 28, 2021Verity Pharmaceuticals's first study: phase 3 study in Urinary Bladder NeoplasmsNew to Verity PharmaceuticalsVerity Pharmaceuticals · NCT05037279 · 540 planned · Canada
- Jul 5, 2023AstraZeneca's first study: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNew to AstraZenecaAstraZeneca · NCT05943106 · 100 enrolled · United States
- Oct 13, 2023Phase 1 study in Non-muscular Invasive Bladder CancerChongqing Zhifei Biological Products · NCT06100653 · 10 enrolled · China
- Jan 28, 2024Chengdu CoenBiotech's first study: phase 1 study in Urinary Bladder NeoplasmsNew to Chengdu CoenBiotechChengdu CoenBiotech · NCT06350838 · 10 enrolled · China
- Jan 28, 2024Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsChengdu CoenBiotech · NCT06241755 · 412 planned · China
- Dec 18, 2024Phase 3 study in Urinary Bladder NeoplasmsChongqing Zhifei Biological Products · NCT06747455 · 439 enrolled · China
- Feb 4, 2025Merck's first study: phase 2 study in Urinary Bladder NeoplasmsNew to MerckMerck · NCT06833073 · 308 planned · United States, Argentina, Australia and more
- Feb 5, 2025Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsImmunityBio · NCT06829823 · 20 planned
- Apr 20, 2026Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsPhase 3 reachedImmunityBio · NCT07551544
Ahead
- Nov 2026Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsImmunityBio · NCT06829823
- Apr 30, 2028Primary completion: phase 3 study in Urinary Bladder NeoplasmsChongqing Zhifei Biological Products · NCT06747455
- Feb 2029Primary completion: phase 3 study in Urinary Bladder NeoplasmsVerity Pharmaceuticals · NCT05037279
- Sep 3, 2031Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT06833073
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities”NCIt, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07551544Non-Muscle Invasive Bladder Neoplasms | 3 | Withdrawn | ImmunityBio | May 2032 | 0 |
| NCT06829823Non-Muscle Invasive Bladder Neoplasms | 2 | Not yet recruiting | ImmunityBio | Nov 2026 | 20 |
| NCT06833073Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Merck | Sep 3, 2031 | 308 |
| NCT06747455Urinary Bladder Neoplasms · China | 3 | Active, not recruiting | Chongqing Zhifei Biological Products | Apr 30, 2028 | 439 |
| NCT06350838Urinary Bladder Neoplasms · China | 1 | Completed | Chengdu CoenBiotech | Feb 13, 2023 | 10 |
| NCT06241755Non-Muscle Invasive Bladder Neoplasms · China | 3 | Recruiting | Chengdu CoenBiotech | Sep 1, 2025 | 412 |
| NCT06100653Non-muscular Invasive Bladder Cancer · China | 1 | Completed | Chongqing Zhifei Biological Products | Jan 1, 2025 | 10 |
| NCT05943106Non-Muscle Invasive Bladder Neoplasms · United States | 3 | Active, not recruiting | AstraZeneca | Jun 16, 2025 | 100 |
| NCT05037279Urinary Bladder Neoplasms · Canada | 3 | Recruiting | Verity Pharmaceuticals | Feb 2029 | 540 |
| NCT04449926Alzheimer Disease · United States | 2 | Completed | Mindful Diagnostics and Therapeutics | Dec 4, 2021 | 49 |
| NCT04165317Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Pfizer | Dec 2, 2024 | 1,068 |
| NCT02795260Tuberculosis | 3 | Completed | Chongqing Zhifei Biological Products | Oct 2016 | 1,802 |
| NCT02389322Tuberculosis · China | 2 | Completed | Chongqing Zhifei Biological Products | Jul 2015 | 1,044 |
| NCT02138734Non-Muscle Invasive Bladder Neoplasms · United States, India, South Africa | 2 | Active, not recruiting | ImmunityBio | Sep 30, 2026 | 369 |
| NCT02010203Urinary Bladder Neoplasms · United States | 2 | Terminated | Heat Biologics | Dec 2017 | 104 |
| NCT01729663Melanoma · Argentina | 3 | UNKNOWN | Laboratorio Pablo Cassará S.R.L. | Dec 2018 | 108 |
How it is read
Names in the registry
- “BCG”, 4 entries
- “BCG for Therapeutic Use”, 4 entries
- “Bacillus Calmette-Guerin”, 1 entry
- “BCG (50 mg) plus ANKTIVA (400 µg)”, 1 entry
- “BCG (50 mg)”, 1 entry
Conditions, from the studies’ own filings
- Non-Muscle Invasive Bladder Neoplasms, 7 studies
- Urinary Bladder Neoplasms, 5 studies
- Tuberculosis, 2 studies
- Alzheimer Disease, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.